313 related articles for article (PubMed ID: 22442493)
1. Inhibitory receptors on lymphocytes: insights from infections.
Odorizzi PM; Wherry EJ
J Immunol; 2012 Apr; 188(7):2957-65. PubMed ID: 22442493
[TBL] [Abstract][Full Text] [Related]
2. Check point inhibitors as therapies for infectious diseases.
Cox MA; Nechanitzky R; Mak TW
Curr Opin Immunol; 2017 Oct; 48():61-67. PubMed ID: 28865357
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.
Emerson DA; Redmond WL
BioDrugs; 2018 Jun; 32(3):221-231. PubMed ID: 29637478
[TBL] [Abstract][Full Text] [Related]
4. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
5. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
[TBL] [Abstract][Full Text] [Related]
6. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.
Teigler JE; Zelinskyy G; Eller MA; Bolton DL; Marovich M; Gordon AD; Alrubayyi A; Alter G; Robb ML; Martin JN; Deeks SG; Michael NL; Dittmer U; Streeck H
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904197
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
8. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Manieri NA; Chiang EY; Grogan JL
Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
10. Basics of PD-1 in self-tolerance, infection, and cancer immunity.
Chikuma S
Int J Clin Oncol; 2016 Jun; 21(3):448-55. PubMed ID: 26864303
[TBL] [Abstract][Full Text] [Related]
11. [T-cell costimulation. Basic mechanisms and new aspects].
Hutloff A
Z Rheumatol; 2011 Sep; 70(7):588-91. PubMed ID: 21858484
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibitory pathways and their importance in immune regulation.
Murakami N; Riella LV
Transplantation; 2014 Jul; 98(1):3-14. PubMed ID: 24978034
[TBL] [Abstract][Full Text] [Related]
13. An atypical KLRG1 in Nile tilapia involves in adaptive immunity as a potential marker for activated T lymphocytes.
Zhang Y; Li K; Li C; Liang W; Li K; Li J; Wei X; Yang J
Fish Shellfish Immunol; 2021 Jun; 113():51-60. PubMed ID: 33798718
[TBL] [Abstract][Full Text] [Related]
14. Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.
Attanasio J; Wherry EJ
Immunity; 2016 May; 44(5):1052-68. PubMed ID: 27192569
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory receptors of lymphocytes and their role in antitumor immunity].
Zakeeva IR; Berezhnoĭ AE; Gnuchev NV; Georgiev GP; Lapin SS
Vopr Onkol; 2007; 53(2):140-9. PubMed ID: 17663166
[No Abstract] [Full Text] [Related]
16. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses.
Frebel H; Oxenius A
Trends Immunol; 2013 May; 34(5):193-9. PubMed ID: 23333205
[TBL] [Abstract][Full Text] [Related]
17. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.
Boer MC; van Meijgaarden KE; Goletti D; Vanini V; Prins C; Ottenhoff TH; Joosten SA
Tuberculosis (Edinb); 2016 Mar; 97():163-71. PubMed ID: 26750180
[TBL] [Abstract][Full Text] [Related]
18. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
19. Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Nguyen LT; Ohashi PS
Nat Rev Immunol; 2015 Jan; 15(1):45-56. PubMed ID: 25534622
[TBL] [Abstract][Full Text] [Related]
20. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.
Watanabe N; Gavrieli M; Sedy JR; Yang J; Fallarino F; Loftin SK; Hurchla MA; Zimmerman N; Sim J; Zang X; Murphy TL; Russell JH; Allison JP; Murphy KM
Nat Immunol; 2003 Jul; 4(7):670-9. PubMed ID: 12796776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
